Sunesis Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 24
Employees
  • Stock Symbol
  • SNSS
Stock Symbol
  • Share Price
  • $1.29
  • (As of Tuesday Closing)

Sunesis General Information

Description

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Contact Information

Website
www.sunesis.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sunesis Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.29 $1.32 $1.17 - $11.30 $23.3M 18.1M 1.48M -$2.20

Sunesis Financials Summary

In Thousands,
USD 		TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 23,841 22,957 23,708 137,615
Revenue 2,193 2,073 237 669
EBITDA (23,117) (22,816) (25,452) (34,053)
Net Income (23,394) (23,330) (26,615) (35,458)
Total Assets 25,506 37,240 15,324 34,334
Total Debt 6,018 6,282 7,396 7,204
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sunesis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sunesis‘s full profile, request access.

Request a free trial

Sunesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization
Biotechnology
South San Francisco, CA
24 As of 2019
00000
000000 - 000 00000

00000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
000000000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

000 0000

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
0000 000000000
Epalinges, Switzerland
000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sunesis Competitors (86)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Infinity Pharmaceuticals Formerly PE-Backed Cambridge, MA 00 00000 00000000 00000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
00000000 Corporation Austin, TX 00 0000 00000000 0000
000000000000 00000 Corporate Backed or Acquired Trevose, PA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
You’re viewing 5 of 86 competitors. Get the full list »

Sunesis Executive Team (17)

Name Title Board Seat Contact Info
Dayton Misfeldt Chief Executive Officer & Chief Financial Officer, Finance
Tina Gullotta Chief Accounting Officer, Accounting & Vice President
Judith Fox Ph.D Chief Scientific Officer & Executive Vice President
Deborah Thomas Ph.D Senior Vice President, Regulatory Affairs, Quality Assurance and Nonclinical Development
Jennifer Smith Ph.D Vice President, Biometrics
You’re viewing 5 of 17 executive team members. Get the full list »

Sunesis Board Members (12)

Name Representing Role Since
David Stump MD Self Board Member 000 0000
Homer Pearce Ph.D Self Board Member 000 0000
James Young Ph.D Self Chairman & Board Member 000 0000
Nicole Onetto MD Sunesis Board Member 000 0000
Paul Walker New Enterprise Associates Board Observer 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Sunesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sunesis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sunesis‘s full profile, request access.

Request a free trial